Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Lonn, E.
Right arrow Articles by Yusuf, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lonn, E.
Right arrow Articles by Yusuf, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies

E. Lonna,1,2, H.C. Gerstein1,2, M. Smieja1,2,3, J.F.E. Mann4 and S. Yusuf1,2

a Department of Medicine, McMaster University, Ontario, Canada
b Population Health Research Institute, McMaster University, Ontario, Canada
c Pathology and Laboratory Medicine, McMaster University, Ontario, Canada
d Department of Nephrology and Hypertension, Schwabing General Hospital, Ludwig Maximillian University, Munchen, Germany

a Eva Lonn, MD, Hamilton General Hospital, 237 Barton Street East, Hamilton, Ontario, Canada L8L 2X2

Abstract

Angiotensin converting enzyme (ACE) inhibitors decrease angiotensin formation, prevent breakdown of bradykinin, and may also act on other peptides of the renin-angiotensin system. Thus, these agents have many effects that can potentially protect the coronary and peripheral vascularature. Which of these "theoretical" mechanisms account for the clinical benefit observed in The Heart Outcomes Prevention Evaluation (HOPE) trial? While the answer to this question is complex and cannot be fully answered, several potential mechanisms have been explored within HOPE and its substudies. These studies demonstrate that ramipril has potent effects on atherosclerosis progression and plaque stabilization as well as on myocardial structure and function. Ramipril also improves glucose metabolism. These effects are dose-dependent but largely blood pressure independent.

Key Words: ACE inhibitors • atherosclerosis • cariovascular disease • HOPE • ramipril • SECURE

References

  1. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, Heart Outcomes Prevention Evaluation Study Investigators. Effect of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153[Abstract/Free Full Text]
  2. Dzau V, Berstein M, Celermeier D, et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther. 2002;16:149–160[CrossRef][Web of Science][Medline]
  3. Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J. Blood pressure reduction and cardiovascular risk in the HOPE study. Lancet. 2001;358:2130–2131[CrossRef][Web of Science][Medline]
  4. Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and of vitamin E on atherosclerosis: the Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation. 2001;103:919–925[Abstract/Free Full Text]
  5. Simon A, Gariepy J, Chironi G, Megnien J-L, Levenson J. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens. 2001;20:159–169
  6. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1990;15:327–331[Abstract/Free Full Text]
  7. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol. 1990;15(Suppl. 5):S65–S72[CrossRef]
  8. Hayek T, Kaplan M, Raz A, Keidar S, Coleman R, Aviram M. Ramipril administration to atherosclerotic mice reduces oxidized low-density lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis. Atherosclerosis. 2002;161:65–74[CrossRef][Web of Science][Medline]
  9. Espeland MA, Craven TE, Riley WA, Corson J, Romant A, Furberg CD. Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thickness. Asymptomatic Carotid Artery Progression Study Research Group. Stroke. 1996;27:480–485[Abstract/Free Full Text]
  10. Bosch J, Yusuf S, Pogue J, et al, HOPE Investigators. Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 2002;324:699–702[Abstract/Free Full Text]
  11. Cashin-Hemphill L, Holmvang G, Chan RC, Pitt B, Dinsmore RE, Lees RS, QUIET Investigators. Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. Quinapril Ischemic Event Trial (QUIET). Am J Cardiol. 1999;83:43–47[CrossRef][Web of Science][Medline]
  12. Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation. 1996;94:258–265[Abstract/Free Full Text]
  13. Teo KK, Burton JR, Buller CE, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation. 2000;102:1748–1754[Abstract/Free Full Text]
  14. MacMahon S, Sharpe N, Gamble G, et alPART-2 Collaborative Research Group. Randomized, placebo-controlled trial of the angiotensin converting enzyme inhibitor, ramipril, in patients with coronary or occlusive arterial disease. Prevention of Atherosclerosis with Ramipril Trial (PART-2). J Am Coll Cardiol. 2000;36:438–443[Abstract/Free Full Text]
  15. Hosomi N, Mizushige K, Ohayama H, et al. Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke. 2001;32:1539–1545[Abstract/Free Full Text]
  16. Gerstein HC, Mann JFE, Yi Q, et al. Albuminuria and risk of cardiovascular events; death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;342:154–160
  17. The Heart Outcomes Prevention Evaluation (HOPE) Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253–259[CrossRef][Web of Science][Medline]
  18. Mann JFE, Gerstein HC, Yi Q, et al. Development of renal disease in people at high cardiovascular risk. J Am Soc Nephrol. 2003;: in press
  19. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–1143[Abstract/Free Full Text]
  20. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365–372[Free Full Text]
  21. Smieja M, Yusuf S, Lonn E, et al. Inflammatory markers and subsequent cardiovascular events in the HOPE trial. Circulation. 2001;17(Suppl II):II–791 Abstract 11363
  22. Gerstein H, Malmberg K, Capes S, Yusuf S. Cardiovascular diseases. Gerstein H, Haynes RB. Evidence-based diabetes care. Ontario, Canada: BC Decker Inc; 2001.
  23. Haffner SM, Miettinen H. Insulin resistance implications for type 2 diabetes mellitus and coronary heart disease. Am J Med. 1997;103:152–162[CrossRef][Web of Science][Medline]
  24. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868–873[Abstract]
  25. Pollare T. Insulin sensitivity and blood lipids during antihypertensive treatment with special reference to ACE inhibition. J Diabet Complications. 1990;4:75–78[CrossRef][Medline]
  26. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BHR, Zinman B. HOPE Study Investigators. Ramipril and the development of diabetes. JAMA. 2001;286:1882–1885[Abstract/Free Full Text]
  27. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet. 1999;353:611–616[CrossRef][Web of Science][Medline]
  28. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003[CrossRef][Web of Science][Medline]
  29. Lonn E, Weitz J, McQueen M, Dzavik V, Gerstein H, Yusuf S. Metabolic and hematologic effects of ramipril in the HOPE trial. Circulation. 2000;102(Suppl II):11–408 Abstract 1127[Abstract/Free Full Text]
  30. Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease: the Framingham Study. Ann Intern Med. 1970;72:813–822
  31. Levy D, Garrison MS, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561–1566[Abstract]
  32. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994;90(4):2056–2069[Free Full Text]
  33. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens. 1992;5:95–110[Web of Science][Medline]
  34. St. John Sutton M, Pfeffer MA, Moye L, et al. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation. 1997;96(10):3294–3299[Abstract/Free Full Text]
  35. Linz W, Scholkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens A. 1989;11:1325–1350[Web of Science][Medline]
  36. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849–1865[Abstract/Free Full Text]
  37. McDonald KM, Garr M, Carlyle PF, et al. Relative effects of alpha 1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog. Circulation. 1994;90(6):3034–3046[Abstract/Free Full Text]
  38. Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor, ramipril. Circulation. 2001;104:1615–1621[Abstract/Free Full Text]
  39. Lonn E, Shaikholeslami R, Yi Q, Bosch J, Magi A, Yusuf S. Effects of ramipril on left ventricular mass and function in normotensive patients with preserved left ventricular function. A substudy of HOPE. J Am Coll Cardiol. 2001;37(Suppl A):165A

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Lonn, E.
Right arrow Articles by Yusuf, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lonn, E.
Right arrow Articles by Yusuf, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?